ArticleInternal and emergency medicine2026
Impact of antithrombotic therapy on management and prognosis of patients hospitalized for upper gastrointestinal bleeding: a multicenter retrospective cohort study.
Article in Internal and emergency medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntithrombotic agents are frequently implicated in upper gastrointestinal bleeding (UGIB), yet their impact on prognosis and management remains unclear. The aim of this study was to assess the impact of pre-existing antithrombotic therapy on the management and prognosis of patients hospitalized for UGIB.
methodsThis study used data from a retrospective, multicenter cohort of adult patients hospitalized for UGIB between January 2019 and December 2020 in Greater Paris University Hospitals. Patients were categorized into four groups according to their pre-existing antithrombotic treatment: antiplatelet therapy, anticoagulant therapy, both, or none. The primary outcome was thirty-day mortality. Secondary outcomes included endoscopy, endoscopic hemostasis, and blood transfusion within 7 days, and intensive care unit admission. Associations were assessed using multivariable logistic regression and reported as adjusted odds ratios (aORs) with 95% confidence intervals (95%CIs).
resultsAmong 928 patients, 226 (24%) were on antiplatelet therapy alone, 154 (17%) on anticoagulant therapy alone, 61 (7%) on combined therapy, and 487 (52%) received no antithrombotic treatment. Thirty-day mortality was 6.9%: 8.4% in the no-antithrombotic group, 6.2% in the antiplatelet group, 4.5% in the anticoagulant group, and 3.3% in the combined therapy group. Compared with the no-antithrombotic group, anticoagulant therapy alone was associated with lower mortality (aOR=0.28, 95% CI 0.10-0.83), while antiplatelet therapy alone or combined therapy were not significantly associated (aOR=0.47, 95% CI 0.19-1.14 and aOR=0.12, 95% CI 0.01-1.11, respectively). Neither anticoagulant nor antiplatelet therapy was associated with secondary outcomes.
conclusionsAntithrombotic therapy had no negative impact on the management or prognosis of patients hospitalized for UGIB.
Indexed as
Identifiers
42850445What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.